The convergence of these two alterations may provide a selective advantage in certain HCC subtypes, as TERT mutations sustain chromosomal stability and cell immortality, while β-catenin activation enhances tumor initiation and progression [16,127,128]. The gene discussed is TERT; the disease is hepatocellular carcinoma.